New drug combo targets tough breast cancer in Real-World study

NCT ID NCT07543250

Not yet recruiting Disease control Sponsor: xuliang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how well a drug called inavolisib works in real-world settings for people with a certain type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will take inavolisib along with hormone therapy, sometimes with another drug. Researchers will track how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inavolisib (a targeted cancer drug) combined with endocrine therapy, with or without a CDK4/6 inhibitor
What this could lead to: If successful, this could provide a new treatment option for people with a specific type of advanced breast cancer, potentially slowing disease progression.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and may not show clear benefits or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.